Advanced Search:
Equity Index Forex Crypto Commodity

CPRX - Catalyst Pharmaceuticals

$15.22  -0.59 (-3.73%)

Updated: 03:09 May 5, 2024 EST

Next Hour's AI Forecast

98.27%

Avg. Accuracy (AI)

$14.94

Next Session's AI Forecast

96.27%

Avg. Accuracy (AI)

$15.84

Next Week's AI Forecast

0%

Trend's Accuracy (AI)

$15.16

Catalyst Pharmaceuticals's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

CATALYST PHARMACEUTICALS - HISTORICAL DATA 6M

  • Last price

    $ 15.22

  • Daily change

    $ -0.59

  • Previous Close

    $ 15.81

  • Last Updated

    03:09 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-0.47 -0.18 0.24 0.17 -0.06

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.69 1.84 2.17 2.36 2.2

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
90% 56.36% 23.48% 47.26%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
15.07 0.47% 15 -2.91% 15.45 4.82% 14.74

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.73 50 0.65 42.2

Catalyst Pharmaceuticals Technical Analysis News

Catalyst Pharmaceuticals

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200
https://www.catalystpharma.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 167
Description

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 3; Compensation: 7.

CATALYST PHARMACEUTICALS'S HOLDERS RANK

List of holders with stock participation in Catalyst Pharmaceuticals.

Holder Rank Holder Shares Date Reported % Out Value